Cannabis Derivative Provides Anti-Cancer Activity in Preclinical Model of Pancreatic Cancer

Boston, MA: The administration of a cannabis-derived flavonoid enhances radiotherapy treatment in preclinical models of pancreatic cancer, according to findings published in the journal Frontiers in Oncology.

A team of researchers affiliated with the Dana-Farber Cancer Institute at Harvard University and the University of Massachusetts assessed the anti-cancer activity of a non-psychoactive cannabis derivative, FBL-03G, in preclinical models of metastatic pancreatic cancer.

Researchers reported that the inclusion of FBL-03G during radiotherapy "induce[d] apoptosis and inhibit[ed] cancer cell concentration" in culture. In animal models, the compound "slowed tumor growth" and was associated with a "significant increase in mice survival."

They concluded, "[T]he FBL-03G results reveal a new potential non-cannabinoid cannabis derivative with major potential for consideration in further investigations in the treatment of pancreatic cancer, where new therapy options are urgently needed." Pancreatic cancer is one of the hardest-to-treat forms of the disease, killing over 90 percent of sufferers within five years.

Preclinical studies identifying anti-cancer activity of cannabinoids date back to the mid-1970s. Far fewer studies exist assessing the therapeutic efficacy of cannabis-specific flavonoids, but recently some scientists have expressed interest in their anti-inflammatory potential.

For more information, contact Paul Armentano, NORML Deputy Director. Full text of the study, "Flavonoid derivative of cannabis demonstrates therapeutic potential in preclinical models of metastatic pancreatic cancer," appears in Frontiers in Oncology.